Enhanced External Counterpulsation in Chronic Heart Failure: Where Do We Stand?

Heart failure has been known as an increasing health burden worldwide and the prevalence is expected to rise more than 23 million in 2030. Chronic heart failure has characteristic of ventricular dysfunction which will cause dyspnea, fatique, and finally some limitation in functional capacity and reduced quality of life. Recent advances in treatment of chronic heart failure may give us option of wide variety of modalities from pharmacologic and nonpharmacologic therapy with invasive and noninvasive approaches. Each has its own benefit and risk. Structural heart disease of heart failure indicates non reversible damage. Thus, treatment will aim to prevent symptoms and improve quality of life. Enhanced external counterpulsation (EECP) was a non-invasive treatment originally to reduce symptom of refractory angina.2-4 In the newest European Society of Cardiology (ESC) guideline for management of stable coronary artery disease 2013, EECP had been approved as class IIa-recommended treatment for refractory angina

Hemostasis and Stem Cell Therapy in Myocardial Infarction

Cardiovascular disease has been well known as the most frequent cause of death in many countries all over the world.1 Acute myocardial infarction (AMI) is a sudden clinical coronary event that has high mortality and morbidity rate. The survivals of AMI will have left ventricle (LV) remodelling and decreased cardiac functions in the following years due to necrosis of cardiomyocites after AMI leading to chronic heart failure. However, revascularization therapy such as percutaneous coronary intervention (PCI) and medications cannot regenerate the necrotic cardiomyocites. Stem cell (SC) therapy as novel strategy in management of AMI has been developing so fast recently. Potential beneficial mechanism of SC therapy after AMI includes myocardial preservation, decreased infarct expansion and myocardial regeneration.2 To date, SC therapy in management of AMI seemed feasible and safe in clinical practice. Number of trials had been conducted to search for promising results and answers to many questions regarding the matter. The TOPCARE-AMI (transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction) with 59 patients showed improvement in ejection fraction and infarct size after 1 year follow-up. The REPAIR-AMI (reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction) trial with larger samples of 204 patients showed improvement in global LVEF at 4 months follow up from 48.3%±9.2% to 53.8%±10.2%.6 A systematic review of SC therapy in AMI with 13 RCT and 811 enrolled patients indicated LV function improvement in short term follow-up

Fragmented QRS (fQRS) in Acute Coronary Syndrome: Is It a More Potential Marker Than Predicted?

Fragmented QRS (fQRS) complexes are electrocardiographic (ECG) findings which reflect impaired ventricular depolarization due to heterogeneous electrical activation of ischemic and or injured myocardium. Therefore, it had been associated with many cardiovascular diseases both ischemic and non-ischemic origin. To date, fQRS is considered a novel and convenient marker of myocardial scar or fibrosis. Thus, it has gained more interest to investigate the potential use of fQRS in cardiac disease, especially in acute coronary syndrome (ACS)

Advanced Gastric Cancer in a Young Patient

Gastric cancer remains the second most common cancer in the world, and is usually found in men, especially those over 50 years of age. The diagnosis is made by endoscopic biopsy. The high frequency of late diagnosis or advanced stages accounts for the overall poor prognosis for this tumor. Surgery is the most frequently employed modality for both cure and palliation. However, most patients present with advanced disease that is incurable. We reported a rare case of young female patient aged 23 years old with advanced gastric carcinoma. The main clinical features were epigastric discomfort, vomiting, and weight loss. An abdominal mass was palpable on physical examination. Endoscopy showed a giant tumor mass causing gastric outlet obstruction, nodular lesion, ulcerative and hemorrhagic. The histopathologic examination revealed mucinous gastric carcinoma. Palliative resection could not be performed because the tumor tightly adhered to adjacent structures. Jejunostomy was performed to allow enteral nutrition. Best supportive care is very important to improve the quality of life

Fragmented QRS (fQRS) in Acute Coronary Syndrome: Is It a More Potential Marker Than Predicted?

Fragmented QRS (fQRS) complexes are electrocardiographic (ECG) findings which reflect impaired ventricular depolarization due to heterogeneous electrical activation of ischemic and or injured myocardium. Therefore, it had been associated with many cardiovascular diseases both ischemic and non-ischemic origin. To date, fQRS is considered a novel and convenient marker of myocardial scar or fibrosis. Thus, it has gained more interest to investigate the potential use of fQRS in cardiac disease, especially in acute coronary syndrome (ACS)

Enhanced External Counterpulsation in Chronic Heart Failure: Where Do We Stand?

Heart failure has been known as an increasing health burden worldwide and the prevalence is expected to rise more than 23 million in 2030. Chronic heart failure has characteristic of ventricular dysfunction which will cause dyspnea, fatique, and finally some limitation in functional capacity and reduced quality of life. Recent advances in treatment of chronic heart failure may give us option of wide variety of modalities from pharmacologic and nonpharmacologic therapy with invasive and noninvasive approaches. Each has its own benefit and risk. Structural heart disease of heart failure indicates non reversible damage. Thus, treatment will aim to prevent symptoms and improve quality of life. Enhanced external counterpulsation (EECP) was a non-invasive treatment originally to reduce symptom of refractory angina.2-4 In the newest European Society of Cardiology (ESC) guideline for management of stable coronary artery disease 2013, EECP had been approved as class IIa-recommended treatment for refractory angina

Pendekatan holistik penyakit kardiovaskular X

x, 209 hl

Prosiding simposium pendekatan holistik penyakit kardiovaskular VII

viii+140hlm.;23c

Pendekatan holistik penyakit kardiovaskular IX

x, 221 hlm; 15x23 c